72 results about "Pelvic pain syndrome" patented technology

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit / hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

The present invention provides compositions and methods for detection, diagnosis, treatment and / or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and / or inhibition of mast cell function (e.g. inhibition of MCP-1 and / or MIP-1α) to treat or prevent chronic pelvic pain syndrome.

The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and / or a lower urinary tract symptom (LUTS) associated with chronic prostatitis and / or chronic pelvic pain syndrome.

Disclosed is a compound useful as an active ingredient for a pharmaceutical composition for treating FAAH-related diseases. Extensive studies have been made on compounds having an FAAH-inhibiting activity, and it is confirmed that a piperazine-1-carboxylate compound having a benzimidazol-2-ylcarbonyl, a benzofuran-2-ylcarbonyl or the like bound to position-4 in the piperazine moiety has an excellent FAAH-inhibiting activity and has an activity to increase the effective bladder capacity, an activity to ameliorate sleep disorder, an anti-diuretic activity and an analgesic activity on lower urinary tract pain including bladder pain. The carbamate compound has an excellent FAAH-inhibiting activity and can be used as a prophylactic and / or therapeutic agent for FAAH-related diseases, particularly nycturia, interstitial cystitis, painful bladder syndrome or chronic non-bacterial prostatitis / chronic pelvic pain syndrome.

Compounds of formula (I),or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

Compounds of formula (I),or pharmaceutically acceptable derivatives thereof, wherein:R1 represents H, C1-6-alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo;R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substituted by CN), or Het;R3 represents OH, CN, Het, —R4—C1-6alkyl, or CONR5R6;R4 represents —CO2—, or —O—;R5 and R6 independently represent H, C1-6alkyl (optionally substituted by OR7) or C3-8cycloalkyl;R7 represents H or C1-6alkyl;Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii)one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C1-6alkyl;R8 represents C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo;R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo;may be useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation / inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

The invention relates to a prostateexosomal protein (PESP) antigen, a specific corresponding antibody and application thereof, and on the basis further acquires a kit based on prostasome leakage protein quantitative indirect enzyme-linked immunoadsorption so as to effectively detect and diagnose chronic prostatitis. By means of reaction system precision detection, stability test and destructive test on the urine detection kit based on PESP antibody-antigen reaction, the reagent quality shows high batch production probability. The application is truly noninvasive, the operation is simple, and the kit has high sensitivity and specificity. The kit can alleviate the patient pain caused by chronic pelvic pain syndrome / chronic prostatitis, and also early diagnosis can further strengthen prevention and treatment of prostate cancer, therefore the kit has wide application prospect.